Bladder Cancer Think Tank

Bladder cancer is the sixth most common cancer in the United States with nearly 75,000 new cases and over 15,000 deaths projected for 2014. With no major changes in these statistics over the past 30 years, there continues to be a tremendous need for more bladder cancer research.  Through our annual Bladder Cancer Think Tank Meeting, BCAN has created an essential vehicle for advancing collaborative research efforts in bladder cancer.  This scientific retreat is the only annual bladder cancer-specific medical meeting in North America.   Since its inception in 2006, the Think Tank meeting has focused on identifying obstacles and creating solutions in bladder cancer research, and has fostered discussions to help define priorities for advancing bladder cancer research.  Invited participants include urologists, oncologists, researchers, patient advocates and industry representatives, all who are dedicated to improving the diagnosis and treatment of bladder cancer.

2014 Bladder Cancer Think Tank
San Diego, California
August 7-9
Program Chair: Andrea Apolo, MD
Program Co-Chair: Ashish Kamat, MD
The 2014 meeting was supported by grants from Abbott Molecular, Inc; Erwin and Stephanie Greenberg, Genentech: A Member of the Roche Group; KARL STORZ Endoscopy-America; Mirati Therapeutics; OncoGenex Pharmaceuticals; Pacific Edge Diagnostics LTD; Photocure; and Viventia Bio, Inc.

 

2013 Bladder Cancer Think Tank

Snowmass Village, Colorado

Program Chair: Yair Lotan, MD

Program Co-Chair: Andrea Apolo, MD

The 2013 meeting was supported by independent educational grants from Abbott Molecular, Inc.; Dendreon Corporation; OncoGenex Pharmaceuticals; and Photocure.

Summary Proceedings

Meeting Participants

 

2012 Bladder Cancer Think Tank

Stowe, Vermont

Program Chair: Matthew Milowsky, MD

Program Co-Chair: Yair Lotan, MD

The 2012 meeting was supported by independent educational grants from  Actium Biosystems, LLC; Abbott Molecular, Inc.; Allergan, Inc., Dendreon Corporation; Endo Pharmaceuticals; OncoGenex Pharmaceuticals; and Predictive Biosciences.

Summary Proceedings

Meeting Participants

 

2011 Bladder Cancer Think Tank

Coronado, California

Program Chair: Seth Lerner, MD

Program Co-Chair: Matthew Milowsky, MD, Bernard Bochner, MD

The 2011 meeting was supported by Morris Lefton and the Lefton family and by independent educational grants from Abbott Molecular, Inc.; Allergan, Inc.; Dendreon Corporation; Endo Pharmaceuticals; GE Healthcare; and Predictive Biosciences.

Summary Proceedings

Meeting Participants

 

2010 Bladder Cancer Think Tank

Traverse City, Michigan

Program Chair: Cheryl Lee, MD

Program Co-Chairs: Seth Lerner, MD and Gary Steinberg, MD

The 2010 meeting was supported by independent educational grants from Abbott Molecular, Inc.; Allergan, Inc.; Endo Pharmaceuticals; GE Healthcare; Predictive Biosciences; and Tengion.

Meeting Participants

 

2009 Bladder Cancer Think Tank

Jackson Hole, Wyoming

Program Chair: Gary Steinberg, MD

Program Co-Chair: Cheryl Lee, MD

The 2009 meeting was supported by independent educational grants grants from Abbott Molecular, Inc.; Boehringer Ingelheim Pharmaceuticals; Endo Pharmaceuticals; GE Healthcare; Predictive Bioscience; and Olympus.

Meeting Participants

 

2008 Bladder Cancer Think Tank

Mt. Tremblant, Quebec

Program Chairs: Michael Jewett, MD, and Victoria Robinson, PhD.

The 2008 meeting was supported by independent educational grants from Abbott Molecular, Inc; Bioniche; GE Healthcare; and Indevus

Meeting Participants

 

2007 Bladder Cancer Think Tank

Cape Cod, Massachusetts

Meeting Participants

 

2006 Bladder Cancer Think Tank

Aspen, Colorado

Meeting Participants

Share this page:Share on FacebookTweet about this on TwitterShare on Google+Share on TumblrShare on LinkedInEmail this to someone
GO TO TOP ^
This website is supported by a generous grant from Photocure
SITE DESIGN: GALANTI DESIGN